New cancer pill TQB3217 enters first human tests

NCT ID NCT07291050

Not yet recruiting Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug called TQB3217 in 40 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. Researchers will also look for any early signs that the drug might shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB3217 tablets (a USP1 inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 40 participants. The drug may not be effective or could cause serious side effects. It will take years before any potential treatment is confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.